Tivantinib Decreases Hepatocyte Growth Factor-Induced BCRP Expression in Hepatocellular Carcinoma HepG2 Cells-Reference-Cited by-同舟云学术

Tivantinib Decreases Hepatocyte Growth Factor-Induced BCRP Expression in Hepatocellular Carcinoma HepG2 Cells

Published:2020-09-01 Issue:9 Volume:43 Page:1421-1425
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Kobayashi Kojiro¹,Higai Koji²,Mukozu Takanori³,Matsui Daigo³,Amanuma Makoto³,Yoshimine Naoyuki³,Ogino Yu³,Matsui Teppei³,Wakui Noritaka³,Shinohara Mie³,Momiyama Koichi³,Daido Yasuko³,Nagai Hidenari³,Igarashi Yoshinori³

Affiliation:

1. Department of Gastroenterology, Toho University Graduate School of Medicine

2. Laboratory of Medical Biochemistry, Faculty of Pharmaceutical Sciences, Toho University

3. Department of Gastroenterology, Toho University Omori Medical Center

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/43/9/43_b19-01100/_pdf

Reference18 articles.

1. 1) Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med., 359, 378–390 (2008).

2. 2) Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 389, 56–66 (2017).

3. 3) Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet, 391, 1163–1173 (2018).

4. 4) Bangaru S, Marrero JA, Singal AG. Review article: new therapeutic interventions for advanced hepatocellular carcinoma. Aliment. Pharmacol. Ther., 51, 78–89 (2020).

5. 5) Arakaki N, Hirono S, Ishii T, Kimoto M, Kawakami S, Nakayama H, Tsubouchi H, Hishida T, Daikuhara Y. Identification and partial characterization of two classes of receptors for human hepatocyte growth factor on adult rat hepatocytes in primary culture. J. Biol. Chem., 267, 7101–7107 (1992).

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Purpurogallin carboxylic acid exhibits synergistic effects with 5‑fluorouracil on liver cancer cells in vitro by targeting ABCG2;Experimental and Therapeutic Medicine;2024-05-08

2. Drug Resistance in Hepatocellular Carcinoma: Theoretical Basis and Therapeutic Aspects;Frontiers in Bioscience-Landmark;2024-02-04

3. A case of hepatic encephalopathy in a patient with unresectable hepatocellular carcinoma and portal vein tumor thrombus successfully treated with shunt embolization and multimodal therapy;Kanzo;2024-01-23

4. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?;Frontiers in Immunology;2021-11-02

5. Insights into Growth Factors in Liver Carcinogenesis and Regeneration: An Ongoing Debate on Minimizing Cancer Recurrence after Liver Resection;Biomedicines;2021-09-04